Vanguard Global Advisers’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
Other funds holding ABUS
Vanguard Global Advisers's ABUS Position: Q3 2026 in Review
Vanguard Global Advisers increased its Arbutus Biopharma (ABUS) stake by 12% in Q3 2026, buying an estimated $32K and bringing the position to 61,802 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.
Vanguard Global Advisers first reported a position in ABUS in Q1 2026 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.
- Vanguard Global Advisers held 61,802 shares of Arbutus Biopharma worth $295K as of Q3 2026.
- Vanguard Global Advisers bought 6,650 Arbutus Biopharma shares in Q3 2026, an estimated $32K.
- Arbutus Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2325 holding.
- Vanguard Global Advisers first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 3 quarters since.
- 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.